Innate Pharma (IPHA) Competitors $2.24 +0.02 (+0.67%) As of 08/22/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPHA vs. NAGE, PHAR, AVBP, SANA, GYRE, OCS, DNA, ATAI, IMTX, and TNGXShould you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), Immatics (IMTX), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Innate Pharma vs. Its Competitors Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks atai Life Sciences Immatics Tango Therapeutics Niagen Bioscience (NASDAQ:NAGE) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Which has more volatility and risk, NAGE or IPHA? Niagen Bioscience has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Do analysts prefer NAGE or IPHA? Niagen Bioscience currently has a consensus price target of $13.42, indicating a potential upside of 34.47%. Innate Pharma has a consensus price target of $11.00, indicating a potential upside of 388.89%. Given Innate Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Innate Pharma is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has better earnings & valuation, NAGE or IPHA? Niagen Bioscience has higher revenue and earnings than Innate Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M7.99$8.55M$0.2147.52Innate Pharma$12.62M16.43-$53.53MN/AN/A Do institutionals & insiders believe in NAGE or IPHA? 15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is NAGE or IPHA more profitable? Niagen Bioscience has a net margin of 15.24% compared to Innate Pharma's net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Innate Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience15.24% 23.12% 15.53% Innate Pharma N/A N/A N/A Does the media favor NAGE or IPHA? In the previous week, Niagen Bioscience had 4 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Niagen Bioscience and 0 mentions for Innate Pharma. Niagen Bioscience's average media sentiment score of 0.11 beat Innate Pharma's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the media. Company Overall Sentiment Niagen Bioscience Neutral Innate Pharma Neutral SummaryNiagen Bioscience beats Innate Pharma on 10 of the 15 factors compared between the two stocks. Get Innate Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPHA vs. The Competition Export to ExcelMetricInnate PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$205.57M$3.11B$5.76B$9.61BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.04Price / Sales16.43352.10436.34104.14Price / CashN/A43.1937.7358.48Price / Book20.458.129.536.61Net Income-$53.53M-$54.72M$3.26B$265.56M7 Day Performance5.39%2.63%2.10%1.95%1 Month Performance13.69%2.78%2.81%-0.37%1 Year Performance1.81%11.01%30.56%19.02% Innate Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPHAInnate Pharma1.7078 of 5 stars$2.25+0.9%$11.00+388.9%-0.4%$205.57M$12.62M0.00220Short Interest ↑Gap UpNAGENiagen Bioscience1.3026 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.13M$116.30M48.19120PHARPharming Group2.3863 of 5 stars$12.39+6.4%$30.00+142.1%+72.3%$798.20M$297.20M-95.31280Gap UpAVBPArriVent BioPharma2.4996 of 5 stars$19.24-1.5%$39.14+103.4%-15.8%$792.31MN/A-4.7940SANASana Biotechnology2.9739 of 5 stars$3.40+2.1%$8.00+135.3%-37.3%$791.90MN/A-3.21380GYREGyre Therapeutics0.0664 of 5 stars$7.85-3.6%N/A-28.7%$783.99M$102.19M785.7940Gap UpOCSOculis3.0126 of 5 stars$18.06+0.9%$35.33+95.6%+50.1%$781.56M$780K-6.842News CoverageEarnings ReportAnalyst ForecastDNAGinkgo Bioworks1.0785 of 5 stars$13.79+4.6%$8.50-38.4%+50.8%$780.25M$227.04M-2.35640ATAIatai Life Sciences3.5697 of 5 stars$4.05+4.4%$11.25+177.8%+254.3%$777.31M$310K-5.8780Analyst DowngradeAnalyst RevisionGap UpIMTXImmatics1.8974 of 5 stars$6.21-1.9%$14.67+136.2%-49.2%$769.41M$168.65M-9.55260News CoverageHigh Trading VolumeTNGXTango Therapeutics1.6777 of 5 stars$7.22+6.6%$10.33+43.1%-37.4%$753.23M$42.07M-5.4390Insider Trade Related Companies and Tools Related Companies NAGE Alternatives PHAR Alternatives AVBP Alternatives SANA Alternatives GYRE Alternatives OCS Alternatives DNA Alternatives ATAI Alternatives IMTX Alternatives TNGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPHA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access